Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Transplant recipients have a high risk to develop skin malignancies. This effect depends on
the one hand on the immunosuppressive drugs themselves (i.e., azathioprine) and relates on
the other hand on the dosage (i.e., calcineurin-inhibitors). Based on the encouraging results
of previous, retrospective studies on patients treated with Sirolimus (SRL), these patients
should be switched to an immunosuppressive regime including SRL, decreasing the dosage of
calcineurin-inhibitors or converting from former immunosuppression. A conversion to a
SRL-based therapy is effective in immunosuppression and safe regarding graft and patient
survival.
This study was designed to assess whether a switch to a SRL-immunosuppressive therapy
decreases the incidence/reoccurrence of skin neoplasm.